3H Health Investment Management is a private equity firm based in Hong Kong, with an additional office in Shanghai, China. The firm specializes in investing in the healthcare sector, focusing on areas such as pharmaceuticals, medical devices, diagnostics, and healthcare services. With a proactive investment approach and a deep understanding of the Chinese market, 3H Health Investment aims to identify and create value in various healthcare opportunities. The firm's extensive industry network and solid fund management experience contribute to its ability to navigate the healthcare landscape effectively.
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.
Edge Medical Robotics, Inc. is a company that specializes in designing and developing advanced surgical equipment. Founded on May 4, 2017, and based in Longgang, Shenzhen, China, the company is dedicated to researching and promoting cutting-edge medical technology. Its mission focuses on enhancing surgical safety and treatment efficacy, aiming to elevate the overall standards of healthcare. Through a commitment to excellence and precision in product development, Edge Medical Robotics strives to contribute positively to the improvement of social health outcomes.
Shanghai Shenqi Medical Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive vascular interventional products. Established in 2014 and based in Shanghai, the company provides a diverse range of medical devices including releasable embolization systems, peripheral microcatheters, distal access guide catheters, drug-coated coronary balloon catheters, and left atrial appendage occluder systems. These products are designed for various medical applications, including cardiovascular intervention, peripheral vascular intervention, neurovascular intervention, and the treatment of structural heart diseases. Shenqi Medical is committed to delivering innovative solutions for the healthcare industry in China.
Citrine Medicine
Series A in 2020
Citrine Medicine is a rare disease-focused pharmaceutical firm.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation MicroPort CardioFlow is dedicated to providing advanced minimally invasive therapies for structural heart diseases with its best-in-class capacities in R&D, manufacturing, marketing, and technical consulting services. We believe in “Focus, Innovation, and Globalization”, and in accordance, we place the utmost importance on saving and improving quality of life for patients. Consequently, we constantly strive to bring the most innovative valvular disease treatment solutions to patients while also operating on a global vision to provide all patients and physicians with world-leading products that are superior, reliable, yet affordable.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.